guest ::
| Home > Publications database > Non-viral technologies can pave the way for CAR-NK cell therapy. |
| Home > Publications database > Non-viral technologies can pave the way for CAR-NK cell therapy. |
| Journal Article (Review Article) | DKFZ-2023-01349 |
; ;
2023
Wiley
Hoboken, NJ
This record in other databases: 
Please use a persistent id in citations: doi:10.1093/jleuko/qiad074
Abstract: Natural killer (NK) cells are a promising platform for cancer immunotherapy. NK cells have high intrinsic killing capability, and the insertion of a chimeric antigen receptor (CAR) can further enhance their anti-tumor potential. In first human trials, CAR-NK cells demonstrated strong clinical activity without therapy-induced side effects. The applicability of NK cells as an 'off-the-shelf' product makes them highly attractive for gene-engineered cell-therapies. Traditionally, viral transduction has been used for gene-editing; however, the use of viral vectors remains a safety concern and is associated with high costs and regulatory requirements. Here, we review the current landscape of non-viral approaches for CAR-NK cell generation, which include transfection of vector particles and electroporation of mRNA and DNA vectors resulting in transient gene-modification and CAR expression. In addition, using non-viral transposon technologies, NK cells can be stably modified ensuring long-lasting CAR expression. Finally, we discuss CRISPR/Cas9 tools to edit key genes for NK cell functionality.
Keyword(s): CAR ; CRISPR ; electroporation ; mRNA ; natural killer cell ; non-viral ; transposon
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Wiley ; Essential Science Indicators ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
